acetylcysteine has been researched along with Diabetic Nephropathies in 26 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (23.08) | 29.6817 |
| 2010's | 16 (61.54) | 24.3611 |
| 2020's | 4 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, W; Guo, J; Han, Q; Hu, L; Li, H; Li, Q; Li, Y; Liao, J; Ma, F; Pan, J; Tang, Z; Zhang, H; Zhang, K | 1 |
| Chang, YP; Cheng, HW; Kuo, CW; Lin, CC; Liu, WS; Lu, SH; Tong, ZJ; Tsai, MT; Tsou, HH; Wang, HT; Yen, PC | 1 |
| Guo, J; Han, Q; Hu, L; Huo, H; Li, H; Li, Y; Liao, J; Ma, F; Pan, J; Tang, Z; Zhang, H | 1 |
| Abdulazim, DO; Amin, M; Csongradi, E; ElAzim, IMA; Elhadidy, S; Fayed, A; Hammad, AA; Hammad, H; Salem, MM; Sharaf El Din, UA; Soliman, KM; Zsom, L | 1 |
| Li, YH; Wan, RJ | 1 |
| Araujo, SRR; Fernandes, TO; Higa, EMS; Lima, DY; Maciel, FR; Mouro, MG; Nogueira, GB; Oliveira, CS; Punaro, GR; Rodrigues, AM | 1 |
| Chen, X; Fang, M | 1 |
| Antunes, AMM; Coelho, NR; Correia, MJ; Gonçalves-Dias, C; Macedo, MP; Monteiro, EC; Morello, J; Pereira, SA; Soto, K | 1 |
| Cha, SK; Chung, CH; Kang, JS; Kim, JH; Lee, ES; Lee, EY; Lee, JH; Lee, SJ; Son, SS | 1 |
| Alicic, RZ; Tuttle, KR | 1 |
| Araujo, SR; Bergamaschi, CT; Buri, MV; Curi, MV; Fernandes, MJ; Ferreira, AT; Higa, EM; Maciel, FR; Nogueira, GB; Paredes-Gamero, EJ; Punaro, GR; Rodrigues, AM | 1 |
| Atar, S; Eizenberg, S; Feldman-Idov, Y; Kristal, B; Marzuq, N; Ofir, P; Shema-Didi, L; Sussan, M | 1 |
| Ai, ZS; Hu, DY; Kang, X; Li, CB; Peng, A | 1 |
| Chung, CH; Kang, JS; Kim, HM; Kim, HS; Kim, YM; Kwon, MH; Lee, ES; Lee, EY; Yadav, D | 1 |
| Ha, H; Kim, YO; Lee, HB; Noh, H; Oh, EY; Seo, JY; Yu, MR | 1 |
| Saklayen, MG; Vallyathan, V; Yap, J | 1 |
| Cheong, SS; Cho, YH; Choi, SW; Hyon, MS; Jang, JS; Kang, SJ; Kim, WJ; Kim, YH; Lee, BK; Lee, CW; Lee, JH; Lee, JY; Lee, NH; Lee, SG; Lee, SW; Park, DW; Park, SJ; Park, SW; Seong, IW; Shin, WY; Suh, J; Yoo, SY; Yun, SC | 1 |
| Gao, B; Ingram, AJ; Krepinsky, JC; Peng, F; Zhang, Y | 1 |
| Ahmad, A; Aloisi, C; Catania, MA; Cuzzocrea, S; Di Paola, R; Esposito, E; Italiano, D; Mazzon, E; Mondello, P; Mondello, S | 1 |
| Aghamohammadzadeh, N; Heydarnejad, M; Khalaj, MR; Mobasseri, M; Noshad, H; Rasi Hashemi, S; Tabrizi, A; Tayebi Khosroshahi, H | 1 |
| Grutzmacher, C; Morrison, ME; Park, S; Sheibani, N; Sorenson, CM; Zhao, Y | 1 |
| Cottalasso, D; Furfaro, AL; Marinari, UM; Menini, S; Odetti, P; Patriarca, S; Pesce, C; Pronzato, MA; Traverso, N | 1 |
| Thaha, M; Tomino, Y; Yogiantoro, M | 1 |
| Al Otaibi, T; Hussain, N; Nampoory, MR | 1 |
| Choi, HJ; Han, HJ; Kim, JH; Lee, JH; Park, SH; Woo, CH | 1 |
| Amano, S; Inagaki, Y; Koga, K; Makita, Z; Okamoto, T; Takeuchi, M; Yamagishi, S | 1 |
4 review(s) available for acetylcysteine and Diabetic Nephropathies
| Article | Year |
|---|---|
Mercapturate Pathway in the Tubulocentric Perspective of Diabetic Kidney Disease.
Topics: Acetylcysteine; Acetyltransferases; Cysteine; Diabetic Nephropathies; Humans; Kidney Tubules, Proximal; Leukotrienes; Oxidative Stress | 2019 |
Novel therapies for diabetic kidney disease.
Topics: Acetylcysteine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antihypertensive Agents; Antioxidants; Bosentan; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Endothelins; Enzyme Inhibitors; Glycation End Products, Advanced; Humans; Hypoglycemic Agents; Indoles; Janus Kinases; Maleimides; Polyamines; Protein Kinase C; Pyridones; Pyridoxamine; Sevelamer; Sulfonamides | 2014 |
N-acetylcysteine for the prevention of contrast-induced nephropathy in patients with pre-existing renal insufficiency or diabetes: a systematic review and meta-analysis.
Topics: Acetylcysteine; Contrast Media; Diabetic Nephropathies; Humans; Kidney Diseases; Randomized Controlled Trials as Topic; Renal Insufficiency | 2015 |
Contrast media nephropathy: in depth review.
Topics: Acetylcysteine; Calcium Channel Blockers; Contrast Media; Diabetic Nephropathies; Dopamine; Endothelin Receptor Antagonists; Humans; Kidney Diseases; Mannitol; Renal Insufficiency; Risk Factors | 2008 |
6 trial(s) available for acetylcysteine and Diabetic Nephropathies
| Article | Year |
|---|---|
N-acetyl-L-cysteine alleviates FUNDC1-mediated mitophagy by regulating mitochondrial dynamics in type 1 diabetic nephropathy canine.
Topics: Acetylcysteine; Animals; Diabetes Mellitus; Diabetic Nephropathies; Dogs; Insulins; Mitochondrial Dynamics; Mitochondrial Proteins; Mitophagy | 2023 |
Is the combination of linagliptin and allopurinol better prophylaxis against post-contrast acute kidney injury? A multicenter prospective randomized controlled study.
Topics: Acetylcysteine; Acute Kidney Injury; Allopurinol; Chemoprevention; Contrast Media; Diabetic Nephropathies; Drug Therapy, Combination; Humans; Kidney Failure, Chronic; Linagliptin; Prospective Studies; Protective Agents; Renal Insufficiency, Chronic; Saline Solution | 2023 |
Prevention of contrast-induced nephropathy with single bolus erythropoietin in patients with diabetic kidney disease: A randomized controlled trial.
Topics: Acetylcysteine; Acute Kidney Injury; Aged; Aged, 80 and over; Biomarkers; Contrast Media; Coronary Angiography; Cystatin C; Cytoprotection; Diabetic Nephropathies; Double-Blind Method; Drug Administration Schedule; Erythropoietin; Female; Humans; Infusions, Intravenous; Iohexol; Israel; Lipocalin-2; Male; Middle Aged; Prospective Studies; Protective Agents; Recombinant Proteins; Renal Insufficiency, Chronic; Risk Factors; Time Factors; Treatment Outcome; Triiodobenzoic Acids | 2016 |
Preventive strategies of renal insufficiency in patients with diabetes undergoing intervention or arteriography (the PREVENT Trial).
Topics: Acetylcysteine; Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Contrast Media; Coronary Angiography; Creatinine; Diabetic Nephropathies; Female; Humans; Male; Middle Aged; Renal Insufficiency; Sodium Bicarbonate; Sodium Chloride | 2011 |
Angiotensin receptor blocker and N-acetyl cysteine for reduction of proteinuria in patients with type 2 diabetes mellitus.
Topics: Acetylcysteine; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Therapy, Combination; Female; Free Radical Scavengers; Humans; Losartan; Male; Middle Aged; Proteinuria; Statistics, Nonparametric | 2012 |
Intravenous N-acetylcysteine during haemodialysis reduces the plasma concentration of homocysteine in patients with end-stage renal disease.
Topics: Acetylcysteine; Adult; Aged; Blood Pressure; Blood Proteins; Diabetic Nephropathies; Drug Administration Schedule; Female; Heart Rate; Hematocrit; Homocysteine; Humans; Hypertension; Infusions, Intravenous; Kidney Calculi; Kidney Failure, Chronic; Male; Middle Aged; Renal Dialysis; Treatment Outcome; Urticaria | 2006 |
16 other study(ies) available for acetylcysteine and Diabetic Nephropathies
| Article | Year |
|---|---|
NAC alleviative ferroptosis in diabetic nephropathy via maintaining mitochondrial redox homeostasis through activating SIRT3-SOD2/Gpx4 pathway.
Topics: Acetylcysteine; Animals; Diabetes Mellitus; Diabetic Nephropathies; Dogs; Ferroptosis; Homeostasis; Insulins; Mammals; Mitochondria; Oxidation-Reduction; Sirtuin 3 | 2022 |
Acrolein plays a culprit role in the pathogenesis of diabetic nephropathy in vitro and in vivo.
Topics: Acetylcysteine; Acrolein; Animals; Carnosine; Cytokines; Diabetes Mellitus; Diabetic Nephropathies; Environmental Pollutants; HEK293 Cells; Humans; Hydralazine; Kidney; Mice; Streptozocin | 2022 |
MicroRNA‑146a/NAPDH oxidase4 decreases reactive oxygen species generation and inflammation in a diabetic nephropathy model.
Topics: Acetylcysteine; Animals; Antagomirs; Cell Line; Diabetic Nephropathies; Disease Models, Animal; Glucose; Humans; Inflammation; Intercellular Adhesion Molecule-1; Male; Mice; Mice, Inbred C57BL; MicroRNAs; NADPH Oxidase 4; Oxidative Stress; Reactive Oxygen Species; Superoxide Dismutase; Vascular Cell Adhesion Molecule-1 | 2018 |
N-acetylcysteine protects against diabetic nephropathy through control of oxidative and nitrosative stress by recovery of nitric oxide in rats.
Topics: Acetylcysteine; Animals; Catalase; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Glutathione; Kidney; Male; Nitric Oxide; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Nitrosative Stress; Oxidative Stress; Protective Agents; Rats, Wistar; Streptozocin; Thiobarbituric Acid Reactive Substances | 2018 |
Oxidative stress mediated mitochondrial damage plays roles in pathogenesis of diabetic nephropathy rat.
Topics: Acetylcysteine; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Female; Kidney Glomerulus; Mitochondria; Oxidative Stress; Rats; Rats, Wistar; Reactive Oxygen Species; Streptozocin | 2018 |
Angiotensin II-mediated MYH9 downregulation causes structural and functional podocyte injury in diabetic kidney disease.
Topics: Acetylcysteine; Actin Cytoskeleton; Angiotensin II; Animals; Calcium; Cell Adhesion; Cell Line, Transformed; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Down-Regulation; Humans; Losartan; Mice; Mice, Inbred C57BL; Microfilament Proteins; Molecular Motor Proteins; Myosin Heavy Chains; NADPH Oxidase 4; Podocytes; Rats; Rats, Inbred Strains; Reactive Oxygen Species; Receptors, Leptin; RNA Interference; TRPC6 Cation Channel | 2019 |
P2X(7) receptor in the kidneys of diabetic rats submitted to aerobic training or to N-acetylcysteine supplementation [corrected].
Topics: Acetylcysteine; Adenosine Triphosphate; Administration, Oral; Albuminuria; Animals; Antioxidants; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Exercise Therapy; Gene Expression; Kidney; Lipid Peroxidation; Male; Oxidative Stress; Physical Conditioning, Animal; Purinergic P2X Receptor Agonists; Rats; Rats, Wistar; Receptors, Purinergic P2X7; Streptozocin | 2014 |
Oleanolic acid and N-acetylcysteine ameliorate diabetic nephropathy through reduction of oxidative stress and endoplasmic reticulum stress in a type 2 diabetic rat model.
Topics: Acetylcysteine; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Endoplasmic Reticulum Stress; Oxidative Stress; Rats; Rats, Inbred OLETF; Reactive Oxygen Species | 2016 |
Histone deacetylase-2 is a key regulator of diabetes- and transforming growth factor-beta1-induced renal injury.
Topics: Acetylcysteine; Amides; Animals; Antioxidants; Biphenyl Compounds; Cell Line; Cell Transdifferentiation; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Enzyme Inhibitors; Extracellular Matrix Proteins; Fibrosis; Gene Expression Regulation; Histone Deacetylase 2; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Kidney; Male; Mice; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Recombinant Proteins; Repressor Proteins; RNA Interference; RNA, Messenger; Transforming Growth Factor beta1; Valproic Acid | 2009 |
Effect of month-long treatment with oral N-acetylcysteine on the oxidative stress and proteinuria in patients with diabetic nephropathy: a pilot study.
Topics: Acetylcysteine; Aged; Antioxidants; Creatinine; Diabetic Nephropathies; Humans; Male; Middle Aged; Oxidative Stress; Pilot Projects; Proteinuria | 2010 |
High glucose-induced RhoA activation requires caveolae and PKCβ1-mediated ROS generation.
Topics: Acetophenones; Acetylcysteine; Animals; Carbazoles; Caveolae; Cyclodextrins; Diabetic Nephropathies; Enzyme Activation; Filipin; Glucose; Indoles; Maleimides; Mesangial Cells; Mice; Mice, Knockout; NADPH Oxidases; Protein Kinase C; Protein Kinase C beta; Rats; Reactive Oxygen Species; rhoA GTP-Binding Protein; RNA, Small Interfering; Tetradecanoylphorbol Acetate; Transcription Factor AP-1; Transforming Growth Factor beta1 | 2012 |
Protective effect of apocynin, a NADPH-oxidase inhibitor, against contrast-induced nephropathy in the diabetic rats: a comparison with n-acetylcysteine.
Topics: Acetophenones; Acetylcysteine; Acute-Phase Proteins; Animals; Apoptosis; Contrast Media; Cytosine; Diabetic Nephropathies; Enzyme Activation; Enzyme Inhibitors; Glutathione Transferase; Iopamidol; Isoenzymes; Kidney Glomerulus; Lipocalin-2; Lipocalins; Male; NADPH Oxidases; Poly(ADP-ribose) Polymerases; Potassium; Proto-Oncogene Proteins; Rats; Rats, Wistar; Sodium; Time Factors; Tyrosine | 2012 |
Aberrant production of extracellular matrix proteins and dysfunction in kidney endothelial cells with a short duration of diabetes.
Topics: Acetylcysteine; Animals; Cell Adhesion; Cell Movement; Diabetes Mellitus; Diabetic Angiopathies; Diabetic Nephropathies; Endothelial Cells; Extracellular Matrix Proteins; Fibronectins; Kidney; Kidney Failure, Chronic; Male; Mice; Neovascularization, Physiologic; Nitric Oxide Synthase Type III; Osteopontin; Vascular Endothelial Growth Factor A | 2013 |
HNE-dependent molecular damage in diabetic nephropathy and its possible prevention by N-acetyl-cysteine and oxerutin.
Topics: Acetylcysteine; Aldehydes; Animals; Apoptosis; Cell Division; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Glycation End Products, Advanced; Hydroxyethylrutoside; Immunohistochemistry; Kidney Glomerulus; Lipid Peroxidation; Lysine; Male; Rats; Rats, Wistar; Taurine | 2005 |
High glucose inhibits renal proximal tubule cell proliferation and involves PKC, oxidative stress, and TGF-beta 1.
Topics: Acetylcysteine; Animals; Antioxidants; Cell Cycle; Cell Division; Cells, Cultured; Diabetic Nephropathies; Glucose; Kidney Tubules, Proximal; Leucine; Lipid Peroxides; Oxidative Stress; Protein Kinase C; Rabbits; Taurine; Thymidine; Transforming Growth Factor beta; Vitamin E | 2001 |
Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells.
Topics: Acetylcysteine; Apoptosis; Cell Division; Cells, Cultured; Chemokine CCL2; Coculture Techniques; Diabetic Nephropathies; Endothelial Growth Factors; Glomerular Mesangium; Glycation End Products, Advanced; Humans; Lymphokines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Suppressor Protein p53; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |